Aimmune Therapeutics (AIMT) Downgraded by BidaskClub to Sell

Share on StockTwits

Aimmune Therapeutics (NASDAQ:AIMT) was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday.

Other equities research analysts have also issued reports about the stock. Wedbush reiterated an “outperform” rating and set a $72.00 price target on shares of Aimmune Therapeutics in a report on Wednesday, May 30th. Credit Suisse Group set a $47.00 price target on shares of Aimmune Therapeutics and gave the company a “buy” rating in a report on Thursday, May 10th. Piper Jaffray Companies set a $62.00 price target on shares of Aimmune Therapeutics and gave the company a “buy” rating in a report on Thursday, April 5th. Zacks Investment Research lowered shares of Aimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, May 11th. Finally, ValuEngine upgraded shares of Aimmune Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. One analyst has rated the stock with a sell rating, one has given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $53.67.

NASDAQ:AIMT opened at $28.27 on Monday. Aimmune Therapeutics has a 52 week low of $18.25 and a 52 week high of $42.00. The firm has a market cap of $1.60 billion, a P/E ratio of -10.83 and a beta of -0.34.

Aimmune Therapeutics (NASDAQ:AIMT) last posted its quarterly earnings results on Tuesday, May 8th. The biotechnology company reported ($0.92) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.71) by ($0.21). During the same quarter in the prior year, the company posted ($0.52) EPS. equities analysts anticipate that Aimmune Therapeutics will post -3.31 earnings per share for the current fiscal year.

In related news, CFO Eric Bjerkholt acquired 1,600 shares of the firm’s stock in a transaction on Wednesday, June 13th. The stock was acquired at an average cost of $30.41 per share, for a total transaction of $48,656.00. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, CEO Stephen George Dilly sold 29,457 shares of the company’s stock in a transaction on Monday, June 11th. The stock was sold at an average price of $30.83, for a total transaction of $908,159.31. Following the completion of the transaction, the chief executive officer now owns 344,765 shares of the company’s stock, valued at $10,629,104.95. The disclosure for this sale can be found here. Insiders sold a total of 364,493 shares of company stock valued at $11,580,119 over the last 90 days. Company insiders own 24.56% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. grew its position in shares of Aimmune Therapeutics by 12.2% in the 1st quarter. BlackRock Inc. now owns 3,078,430 shares of the biotechnology company’s stock worth $97,984,000 after buying an additional 334,618 shares during the period. Eventide Asset Management LLC grew its position in shares of Aimmune Therapeutics by 27.6% in the 1st quarter. Eventide Asset Management LLC now owns 1,564,983 shares of the biotechnology company’s stock worth $49,813,000 after buying an additional 338,983 shares during the period. Alliancebernstein L.P. grew its position in shares of Aimmune Therapeutics by 109.5% in the 4th quarter. Alliancebernstein L.P. now owns 1,400,281 shares of the biotechnology company’s stock worth $52,959,000 after buying an additional 731,927 shares during the period. Palo Alto Investors LP grew its position in shares of Aimmune Therapeutics by 18.3% in the 1st quarter. Palo Alto Investors LP now owns 1,356,514 shares of the biotechnology company’s stock worth $43,178,000 after buying an additional 210,095 shares during the period. Finally, Foresite Capital Management III LLC grew its position in shares of Aimmune Therapeutics by 22.3% in the 1st quarter. Foresite Capital Management III LLC now owns 935,020 shares of the biotechnology company’s stock worth $29,762,000 after buying an additional 170,196 shares during the period. Institutional investors and hedge funds own 79.49% of the company’s stock.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply